Latest

Ozempic

·April 23, 2026·8 min read

GLP-1 Drugs Target the Roots of Dementia

A comprehensive review of 30 studies finds that GLP-1 receptor agonists are effective at tackling the biological drivers of Alzheimer’s disease.

This shows a woman on a scale with people pointing at her.

Featured Neuroscience Psychology

·April 17, 2026·8 min read

Decoding the Shame Associated with Ozempic Weight Loss

Women using GLP-1 drugs for weight loss face higher levels of stigma than those using diet and exercise, with many critics viewing the medication as a "shortcut."

Featured Genetics Neuroscience

·April 8, 2026·8 min read

Ozempic Weight Loss Success Varies by DNA

A new study of 28,000 people identifies genetic markers in the GLP1R and GIPR genes that explain why some patients lose more weight or experience more nausea on GLP-1 drugs.

This shows a woman holding her head in pain.

Featured Neurology Neuroscience

·March 2, 2026·7 min read

Beyond Weight Loss: Ozempic Linked to Migraine Reduction

Unexpected relief. New research shows that patients taking GLP-1 drugs for diabetes or weight loss also experience fewer emergency room visits and need fewer medications for their chronic migraines.

Featured Neuroscience

·May 26, 2025·4 min read

Brainstem Neurons Hold Key to Semaglutide’s Weight Loss Effects

Researchers have identified a specific group of brainstem neurons that mediate the appetite-reducing and weight-loss effects of semaglutide without triggering side effects like nausea. In mice, activating these neurons led to reduced food intake and fat loss, mimicking the drug’s benefits.

Featured Neuroscience Psychology

·April 18, 2025·5 min read

Potential Depression Risk Linked to Ozempic-Like Drugs

A new international study reveals a possible connection between GLP1 receptor agonists—used in drugs like Ozempic—and increased risk of depression and suicidal ideation, especially in people with low dopamine function. Researchers used advanced pharmacogenomic tools to identify genetic pathways that may be vulnerable to dopamine dysregulation when exposed to these medications.

Featured Neurology Neuroscience

·April 16, 2025·5 min read

Ozempic Linked to Lower Alzheimer’s Risk

A new study suggests that two widely used Type 2 diabetes medications—GLP-1 receptor agonists and SGLT2 inhibitors—may help reduce the risk of Alzheimer’s disease and related dementias. Researchers analyzed Medicare data and found that patients taking these drugs had significantly lower rates of cognitive decline compared to those using other glucose-lowering medications.

Featured Neuroscience

·February 12, 2025·7 min read

Semaglutide Shows Promise in Reducing Alcohol Cravings and Consumption

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol consumption. Researchers found that weekly injections of semaglutide decreased alcohol cravings, drinking quantity, and heavy drinking days in adults with alcohol use disorder. Participants receiving semaglutide consumed less alcohol in a controlled lab setting and reported reduced cravings compared to those receiving a placebo.

This shows the outline of a person and a brain.

Featured Neuroscience

·January 20, 2025·6 min read

GLP-1 Drugs Offer Brain Benefits but May Pose Other Health Risks

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health benefits, including reduced risks of addiction, Alzheimer’s, and dementia. However, they also pose risks for pancreatitis and kidney conditions, emphasizing the need for careful monitoring.

Featured Neurology Neuroscience

·October 24, 2024·4 min read

Ozempic Shows Potential in Lowering Alzheimer’s Risk

New research suggests that semaglutide, a popular diabetes and weight-loss drug, may reduce the risk of Alzheimer’s disease in people with type 2 diabetes. The study compared semaglutide to seven other anti-diabetic drugs and found it was linked to a significantly lower risk of developing Alzheimer’s.

Featured Neuroscience Psychology

·September 4, 2024·5 min read

No Link Found Between Ozempic and Suicide Risk

A new study has found no evidence that GLP-1 analogues, common diabetes drugs, increase the risk of suicide, self-harm, or related mental health issues. Researchers analyzed data from around 300,000 people treated with these medications and found no clear link between the drugs and mental health risks.

Featured Genetics Neuroscience

·July 15, 2024·5 min read

Adjusting Proteins Increases Ozempic’s Effectiveness

Adjusting melanocortin proteins in the brain enhances the effectiveness of GLP-1 diabetes and weight-loss drugs. By inhibiting MC3R or activating MC4R, mice showed increased sensitivity to these drugs, leading to more significant weight loss and reduced feeding without additional side effects.